Company intelligence / Profile preview

Dr. Raven's

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Raven Biotechnologies was a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody therapeutics for the treatment of cancer. The company utilized a proprietary platform to identify novel cell-surface antigens specifically expressed on cancer cells and cancer stem cells. By targeting these unique markers, Raven aimed to develop highly specific therapies for various solid tumors, including pancreatic, colorectal, and lung cancers. The company's lead programs were integrated into the pipeline of MacroGenics following its acquisition in 2008.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Dr. Raven's.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dr. Raven's.

Explore the full profile